Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K020007
    Manufacturer
    Date Cleared
    2002-03-21

    (78 days)

    Product Code
    Regulation Number
    878.3300
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    SAFYRE SLING SYSTEM

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Safyre Sling is to be permanently implanted in women, for the treatment of stress urinary incontinence grades II and III (due to bladder hypermobility and/or Intrinsic Sphincter Deficiency) acting as a urethral support.

    Device Description

    PROMEDON's Sling, SAFYRE, is manufactured with biocompatible silicone elastomers and polypropylene. It is a permanent implant and is offered as a single use sterile product. Safyre consists of a pierced polypropylene mesh between two silicone columns that are made of multiple cone-shaped soft tissue anchors. The e units are the basis of the self anchoring system. The polypropylene shilles on the mid-urethra and the interconnective tissue grows among me the perforations between the vaginal flap and the urethra, which leads to internation of the implant without a loss of vascularization between the bladder and the vagina. The two columns are fixed to the abdominal fascia. This self anchoring is enough to keep the sling in its place when there is an important muscular activity, such as coughing or other strains.

    AI/ML Overview

    The provided text is a 510(k) Summary for the SAFYRE Sling, which is a premarket notification for a medical device. This document does NOT contain information about acceptance criteria or a study proving the device meets acceptance criteria.

    The document states:

    • "Bench testing and biocompatibility testing was performed on the SAFYRE Sling." (Page 2, Section 7. Performance Testing). However, no details about the results, acceptance criteria, or specific study designs for these tests are provided.
    • The FDA letter (Pages 3-4) confirms that the device was found "substantially equivalent" to predicate devices, which is a regulatory determination based on comparison to existing legally marketed devices, not typically on a new performance study proving acceptance criteria.

    Therefore, I cannot provide the requested information as it is not present in the given text. The document focuses on establishing substantial equivalence to predicate devices, not on presenting detailed performance study results against specific acceptance criteria.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1